echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Charlize Theu: Mitochondrial damage confirmed to be an early event of Alzheimer's disease

    Charlize Theu: Mitochondrial damage confirmed to be an early event of Alzheimer's disease

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    To test the hypothesis that lipoprotein E subtypes affect mitochondrial structure and function associated with cognitive impairment in Alzheimer's disease (AD), researchers recently systematically studied the effects of lipoprotein E subtypes on mitochondrial biodynamics and dynamics, oxidative stress, synapses, and cognitive performance in ADThe researchers obtained posthumous human brain samples and measured the protein responsible for the bio-production of mitochondria (peroxidase proliferator-activated receptor-cyplidie-1 alpha-1 alpha-1-1-and-sirtuin 3 (SIRT3) as well as mitochondrial dynamics (mitofusin 1 (MFN1)mitofusin 2 (MFN2) and dynamic protein-like protein s1 (DLP1), oxidative stress (superoxide dismutase 2 (SOD2) and fork box protein O3a (Foxo3a)) and synapses (post-synaptic density protein 95 (PSD95) and synapsin 1 (Syn1) associated with proteinsThe study included a total of 46 samples, including lipoprotein E-4 carriers (n s 21) and non-carriers (n s 25)The researchers compared the levels of these proteins between ApoE-4 carriers and non-carriersApoE-?4 is associated with impaired structure and function of mitochondria, oxidative stress and synaptic integrityCorrelation analysis showed that mitochondrial proteins and synaptic proteins were closely related to cognitive abilityTherefore, lipoprotein E subtypes affect mitochondrial structure and function and are likely to lead to changes in oxidative stress, synapses and cognitive functionThese mitochondrial-related proteins may be a harbinger of cognitive decline in ApoE-4 carriers and provide new therapeutic targets for prevention and treatment of AD
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.